Evidence map›Paper›PMID 27930740›Full record

ArticlePloS one2016

Facilitators and Barriers of Antiretroviral Therapy Initiation among HIV Discordant Couples in Kenya: Qualitative Insights from a Pre-Exposure Prophylaxis Implementation Study.

Rena C Patel, Josephine Odoyo, Keerthana Anand, Gaelen Stanford-Moore, Imeldah Wakhungu, Elizabeth A Bukusi, Jared M Baeten, Joelle M Brown

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rena C PatelDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, United States of America.ORCID http://orcid.org/0000-0001-9893-5856
Josephine OdoyoCentre for Microbiologic Research, Kenya Medical Research Institute, Kisumu, Kenya.
Keerthana AnandNorthwestern University, Chicago, IL, United States of America.
Gaelen Stanford-MooreSchool of Medicine, University of California, San Francisco, CA, United States of America.
Imeldah WakhunguCentre for Microbiologic Research, Kenya Medical Research Institute, Kisumu, Kenya.
Elizabeth A BukusiCentre for Microbiologic Research, Kenya Medical Research Institute, Kisumu, Kenya.
Jared M BaetenDepartments of Epidemiology, Global Health, and Medicine, University of Washington, Seattle, WA, United States of America.
Joelle M BrownDepartments of Epidemiology and Biostatistics and Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA, United States of America.

Funding

Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
BIOLOGY OF INFECTIOUS DISEASES TRAINING PROGRAMT32AI007641 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY · 2000 to 2026
$6.9M
Optimizing Antiretroviral-Based HIV Prevention for HIV Serodiscordant CouplesR01MH095507 · NIMH · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED · 2011 to 2020
$6.1M
Impact and Cost-effectiveness of Safer Conception Strategies for HIV PreventionK01MH100994 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BROWN, JOELLE MORGAN · 2013 to 2017
$893k
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implantsK23AI120855 · NIAID · UNIVERSITY OF WASHINGTON · PI PATEL, RENA CHIMAN · 2015 to 2019
$850k
NCATS NIH HHS KL2 TR000143NIAID NIH HHS K23 AI120855NIAID NIH HHS T32 AI007641NIMH NIH HHS K01 MH100994NIMH NIH HHS R01 MH095507
6 · The paper itself

Abstract

introductionThe World Health Organization now recommends antiretroviral therapy (ART) initiation for all HIV-infected individuals regardless of CD4 cell count or disease status. Understanding the facilitators and barriers to initiation of and adherence to ART is essential to successful scale-up of "universal" ART.

methodsTo investigate facilitators and barriers to ART initiation, we conducted 44 in-depth individual or couple interviews with 63 participants (33 participants with HIV and 30 without HIV) already enrolled in a prospective implementation study of oral antiretroviral-based prevention in Kisumu, Kenya between August and September 2014. A semi-structured interview guided discussions on: 1) perceived advantages and disadvantages of ART; 2) reasons for accepting or declining ART initiation; and 3) influence of prevention of transmission to partner or infant influencing ART use. Transcripts from the interviews were iteratively analyzed using inductive content analysis.

resultsHIV-infected participants indicated that living a healthier life, preventing HIV transmission to others, and appearing "normal" or "healthy" again facilitated their initiation of ART. While appearing "normal" allowed these individuals to interact with their communities without stigmatization, they also perceived community opposition to their initiating ART, because appearing "normal" again prevented community members from easily identifying infected individuals in their community. Denial of diagnosis, disclosure stigma, perceived side-effects, and challenges in obtaining refills were additional barriers to ART initiation.

conclusionsCommunity perceptions play an important role in both facilitating and inhibiting ART initiation. Perceived stigma, including perceived community opposition to widespread ART use, is an important barrier to ART initiation. Addressing such barriers, while capitalizing on facilitators, to ART initiation should be central to universal ART scale-up efforts.

Indexed as

AdultAnti-HIV AgentsFamily CharacteristicsFemaleHIV InfectionsHumansInterviews as TopicKenyaMalePatient Acceptance of Health CarePre-Exposure ProphylaxisQualitative ResearchYoung AdultAnti-HIV Agents

Identifiers

PMID27930740
PMCPMC5145201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.